This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SCHAUMBURG, Ill., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced the launch of its National Research Center ("NRC") in Chengdu, China. Based in Chengdu's Bio-Technology Park, the NRC will focus on process and method development of technically challenging specialty injectable pharmaceuticals.
Staffed with an international team of experienced research scientists, the center will initially focus on developing both liquid and lypholization products for Sagent China Pharmaceuticals ("SCP"), Sagent's FDA-inspected manufacturing facility, also located in Chengdu.
"Building a first class development center in support of our manufacturing capabilities is a natural next step in our strategic evolution," said Jeffrey M. Yordon, chief executive officer and chairman of the board of Sagent. "The NRC is equipped with state-of-the-art equipment and staffed with a team of global experts in specialty injectable development. We are proud of the progress of our team in China and pleased to provide increased support for the rapid development of additional products to be manufactured at SCP."
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.